Pharos iBio Co., Ltd. (KOSDAQ:388870)

South Korea flag South Korea · Delayed Price · Currency is KRW
8,700.00
-40.00 (-0.46%)
At close: Mar 9, 2026
21.34%
Market Cap 112.63B
Revenue (ttm) n/a
Net Income (ttm) -9.82B
Shares Out 12.95M
EPS (ttm) -759.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 173,067
Average Volume 182,958
Open 8,740.00
Previous Close 8,740.00
Day's Range 8,350.00 - 8,860.00
52-Week Range 4,630.00 - 12,120.00
Beta -0.22
RSI 47.59
Earnings Date Mar 17, 2026

About Pharos iBio

Pharos iBio Co., Ltd. engages in the development of treatments for rare and refractory diseases using AI based drug development platform in South Korea. It develops PHI-101-AML that is in phase 1 clinical trial for the treatment of refractory/recurrent acute myelogenous leukemia (AML); PHI-101-OC that is in phase 1 clinical trial for the treatment of recurrent ovarian cancer; PHI-501 for refractory solid cancer; PHI-301 for the treatment of refractory lung cancer; and PHI-601 for the treatment of menin inhibitor. The company was founded in 2016... [Read more]

Industry Pharmaceutical Preparations
Founded 2016
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 388870
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.